Audentes Therapeutics Inc

Audentes Therapeutics — Investor Presentation (November 2016)

34 slides from Audentes Therapeutics's investor presentation, Nov 29, 2016

  1. Slide 1: Audentes Therapeutics Corporate Overview, November 2016

    Courageous Bold November Audentes NASDAQ: Exhibit Effort.™ 99.1 Corporate 2016 BOLD Patients.Overview

  2. Slide 2: Forward-Looking Statements

    AUDENTES Safe Except uncertainties, you Forward-looking application commercialization actions, to the Certain reliable. Theadate number can trademarks Harbor for information levels of identify However, statements this and ofTHERAPEUTICS assumptions of risks, presentation, Clinical included forward-l

  3. Slide 3: Audentes Therapeutics

    AUDENTES Audentes Rare Internal Focused Proven Preliminary disease management manufacturing selection Therapeutics clinical and THERAPEUTICS AAV criteria data team gene Developing provides from for and therapy current lead leading core C 3programs gene strategic ORPORATE and strategic lifetherapy fu

  4. Slide 4: Leadership Team with Outstanding Experience

    AUDENTES Matthew Natalie Thomas Suyash John Mary David Senior Audentes 85 employees Gray, Newman Nagler VP VP, Holles Prasad, Soloway Patterson Therapeutics and Research Regulatory Human Ph.D. THERAPEUTICS based Chief M.D. Senior Resources President in and Operating Senior Affairs San Leadership VP

  5. Slide 5: Gene Therapy Sector Gaining Momentum

    AUDENTES Multiple H C –P AAV9-SMN –A –Disease –Compelling –Encouraging –FDA AveXis AAV arkinson’s—Sanfilippo horoideremia—MPS emophilia devastating Gene has Releases 2017 state, indicated Therapy A&B—Spinal for proof-of-concept THERAPEUTICS safety Sector dose rare SMA Favorable disease Gaining poten

  6. Slide 6: Focused Value Drivers and Approach

    Focused VALUE AUDENTES High-value Serious Monogenic High Leading Well-characterized Optimized In-house Reduced Proof-of-concept Clear Opportunities potential clinical life-threatening AAV DRIVERS Approach development process expression targets diseases APPROACH THERAPEUTICS efficacy science for fors

  7. Slide 7: Robust Pipeline

    AUDENTES Robust AT307 AT982 AT342 AT132 (Investigator Pipeline THERAPEUTICS Sponsored) C 7 ORPORATE PRESENTATION

  8. Slide 8: Internal Manufacturing Capability

    AUDENTES S O I23Audentes A –P Internal n-house 8,000 uperior lanned pportunity dditional x 500Lsquare cGMP to control QC bioreactor facility be capacity for lab THERAPEUTICS capable foot manufacturing rapid over for established cGMP (~5,000L) scale critical timelines, addition of commercial in manuf

  9. Slide 9: Manufacturing Leadership Position

    AUDENTES Audentes Leadership Mammalian Natural Robust, Initial Facility Production Significant Essential Facilitates Continued Robust Larger Additional capacity scale process host qualified industrial for cGMP regulatory process production regulatory investment at Position cell-based bioreactors for

  10. Slide 10: AT132 X-Linked Myotubular Myopathy

    AUDENTES AT132 X-LINKED THERAPEUTICS MYOTUBULAR C 10 MYOPATHY ORPORATE PRESENTATION

  11. Slide 11: Serious, Monogenic Rare Disease: XLMTM

    AUDENTES Serious, Significant Estimated Incidence: Monogenic, MTM1 Target AAV8 Clear Respiratory Neuromuscular Muscle Hnia, XLMTM clinical Beggs, for effectively gene tissue biopsy life-threatening A AAV 50% 1impairment Fatal function well-understood in encodes et THERAPEUTICS measures is50K mortali

  12. Slide 12: Dramatic Improvement in Survival in XLMTM Mouse and Dog Models

    AUDENTES A M. Weeks XLMTM 05XLMTM+AT132 150 Percent 100 Untreated MTM1 Normal P Single 2.5 0?single K. 0.001 x 1014 Childers injection of KO survival (n=13) Mice treatment Canine (n=2) age MTM1 vg/kg Mouse + THERAPEUTICS AT132 + et Placebo Placebo, ofAT132 Model al., (n=3) KO with 3Model x(3 (5 Sci

  13. Slide 13: Treatment with AT132 Results in Dramatic Improvement and Survival in XLMTM Dogs

    AUDENTES Treatment *Dogs 3, 4with andTHERAPEUTICS AT132 5, the three Results dogsinC treated Dramatic 13 ORPORATE in the Improvement proof-of-concept PRESENTATION and Survival canine in study, XLMTM achieved Dogsa statistically significant improvement in survival.

  14. Slide 14: Systemic AT132 Improves Outcomes in XLMTM Dogs in a Dose Dependent Manner

    AUDENTES Systemic Mack, Infusion n=19 AT132 nN 46Arm X 3M Dose Limb Survival Respiratory Neurological Gait Vector Histology Transgene 10%-40% 100% ormal LMTM easure Dependent Strength at D., Copy Improves treated high-dose ofDelivery +at 5.0 2.5 8.0 et. Expression AT132 Placebo Function mid-dose Num

  15. Slide 15: AT132 Clinical Development Path

    AUDENTES AT132 RECENSUS XLMTM Historical Clinical INCEPTUS Ongoing, Longitudinal Facilitate Phase ASPIRO Open-label, -Key Primary Preliminary CHOP-INTEND Meanefficacy 1/2 Clinical Inspiratory Assessment analysis enrollment natural prospective Study control dose data Retrospective measures: baseline

  16. Slide 16: AT132 Opportunity Summary

    AT132 Opportunity Compelling Devastating significant Clear Strong 16 AUDENTES dose- safety for XLMTM expected Potential Market rare Summary profile THERAPEUTICS PathPotential Q4:17 for to Approval expedited supportdisease, dependent value CORPORATE story no therapies efficacy impact PRESENTATION on

  17. Slide 17: AT342 Crigler-Najjar Syndrome

    AUDENTES AT342 CRIGLER-NAJJAR THERAPEUTICS SYNDROME C 17 ORPORATE PRESENTATION

  18. Slide 18: Crigler-Najjar Syndrome: Serious, Monogenic Rare Disease

    AUDENTES Crigler-Najjar A Serious, Significant Current Estimated Monogenic UGT1A1 Target AAV8 Liver Clear Serum Time Bortolussi Rareon tissue clinical for effectively bilirubin Disease treatments: life-threatening phototherapy gene AAV incidence et. bilirubin ,iswell-understood THERAPEUTICS al, meas

  19. Slide 19: AT342 Rapidly Reduces Bilirubin Levels in Mouse Model

    01AUDENTES -10 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 60 50 40 30 20 2.5 AT342 Vehicle In B –R A Total Days 0esults ilirubin single axpreviously E12 E13 1012 1013 Bilirubin Rapidly suggested Control tail levels GC/kg vg/kg vein THERAPEUTICS Levels reported Reduces were (n=5) (n=5) injection thatreduced

  20. Slide 20: AT342 Clinical Development Plan

    AUDENTES AT342 Clinical Prospective Longitudinal Facilitate Phase Open-label, Key S -T Primary Preliminary erum imeefficacy on 1/2 bilirubin Development Assessment analysis phototherapy enrollment Run-in Clinical evaluation dose data measures: baseline THERAPEUTICS expected at escalation, Study Stud

  21. Slide 21: AT342 Opportunity Summary

    AT342 Opportunity Compelling Path significant for 21 AUDENTES liver-directed to for Approval Crigler-Najjar and Market Summary expected THERAPEUTICS AAV8 Devastating Potential therapies Q4:17disease, support CORPORATE Potential current value for story therapies expedited PRESENTATION durable subopti

  22. Slide 22: AT982 Pompe Disease

    AUDENTES AT982 POMPE THERAPEUTICS DISEASE C 22 ORPORATE PRESENTATION

  23. Slide 23: Pompe Disease: Serious, Monogenic Rare Disease

    AUDENTES Pompe Lipinksi, Serious, Severe Spectrum Estimated Monogenic, Gene Target Efficacy AAV9 Clear Respiratory Neuromuscular Muscleencodes clinical for penetrates muscle Disease biopsy life-threatening of Shawn. of AAV incidence ERT function well-understood disease THERAPEUTICS measures lysosoma

  24. Slide 24: Treatment with AT982 Results in Significant Improvement in Pompe KO Mice

    AUDENTES Treatment Falk GAA Total PR P Single $ Interval 0.0001 0.05 0.001 0.01 etRespiratory Activity injection al, Molecular with Restored THERAPEUTICS AT982 ofCycle 5 xTherapy–Methods to1012 Results Normal Timevg/kg Improved In(3 CSignificant AT982 mo) 24 ORPORATE & (3versus Clinical mo) Improvem

  25. Slide 25: AT982 Program Overview

    AUDENTES Univ. Sponsor Intrathecal Systemic Intramuscular Status Audentes IND Tibialis Target Proof-of-concept Skeletal CNS, Key GAA Improve muscle Completed Manufacturing Robust AT982 BOLD Orphan Clinical Ready Enabling Activity of PNS, Program holds function large-scale Anterior Drug Muscle, Flori

  26. Slide 26: AT982 Opportunity Summary

    AT982 Opportunity Compelling Path Preclinical plan Designation Improvement 26 AUDENTES to for evaluate Approval Pompe POC Market granted Summary in multiple United THERAPEUTICS Devastating Potential in States routes disease, and of administration E.U. CORPORATE current Rare disease therapies Opportu

  27. Slide 27: AT307 Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

    AUDENTES AT307 CATECHOLAMINERGIC THERAPEUTICS C 27 POLYMORPHIC ORPORATE PRESENTATION VENTRICULAR TACHYCARDIA (CPVT)

  28. Slide 28: CASQ2-CPVT: Serious, Monogenic Rare Disease

    AUDENTES Serious, Ventricular Prevalence Monogenic Autosomal Target AAV9 Heart Clear Electrocardiogram Episodes CASQ2-CPVT Cerrone clinical tissue for vector et life-threatening of AAV al., estimated recessive arrhythmias ,VT iswell-understood THERAPEUTICS capsid measures Circulation otherwise A gen

  29. Slide 29: AT307 Prototype Reduces VT in Newborn and Adult Mice

    AUDENTES AT307 A N –R Denegri Newborn Adult P eduction ear <single 0.001 0.05 normal Mice Prototype et administration Mice in al.,levels pre-arrhythmic THERAPEUTICS Circulation, Prevents of CASQ2 of an VT 2014 events AT307 in protein CNewborn 29 and prototype ORPORATE expression ventricular Miceachi

  30. Slide 30: AT307 Opportunity Summary

    AT307 Opportunity Compelling Path Proof-of-Concept Robust drug 30 AUDENTES toOrphan for Approval CASQ2-CPVT Market Summary Drug THERAPEUTICS Devastating IND/CTA Potential pricing planned disease, Reduction CORPORATE incurrent 2017 in ventricular Measurable therapies PRESENTATION Designation suboptim

  31. Slide 31: Financial Overview

    AUDENTES THERAPEUTICS FINANCIAL OVERVIEW C 31 ORPORATE PRESENTATION

  32. Slide 32: Financial Summary

    AUDENTES Financial $85M September Funded P –A 2015 R&D Q3:16 Q2:16 (Unaudited) Q1:16 (Audited) $20.2M G&A $12.5M $$11.7M Loss $2.9M $(15.5M) $(14.2M) $(10.5M) $(26.7M) reliminary dvance 7.9M 6.5M 2.6M 2.5M from YE Expense IPO toAT307 Summary achieve Ops. in 30, data THERAPEUTICS July 2016 (CASQ2-CPV

  33. Slide 33: Audentes Highlights and Catalysts

    AUDENTES Audentes Industry-leading Catalysts Manufacturing Leadership Expertise Focus Compelling Internal Future Proven Leading INDs/CTAs Preliminary capacity management cGMP life Highlights clinical pipeline for sciences THERAPEUTICS manufacturing 3expansion AAV programs data team of investors gene

  34. Slide 34: Audentes Corporate Overview, November 2016

    Courageous Bold November Audentes NASDAQ: Effort.™ Corporate 2016 BOLD Patients.Overview

Audentes Therapeutics — Investor Presentation (November 2016) on 6ix